Jiang H, Bai X
J Multidiscip Healthc. 2025; 18:1147-1162.
PMID: 40026868
PMC: 11872101.
DOI: 10.2147/JMDH.S501551.
Waszczuk-Gajda A, Vesole D, Malyszko J, Jurczyszyn A, Wrobel T, Drozd-Sokolowska J
Arch Med Sci. 2025; 20(6):1864-1873.
PMID: 39967949
PMC: 11831329.
DOI: 10.5114/aoms.2020.93442.
Bai H, Zhang C, Zhao A, Tang W, Zhang L
Ther Adv Hematol. 2025; 16:20406207251319593.
PMID: 39963097
PMC: 11831653.
DOI: 10.1177/20406207251319593.
Utsu Y, Isono Y, Masuda S, Arai H, Shimoji S, Matsumoto R
Ann Hematol. 2025; 104(1):573-579.
PMID: 39870910
PMC: 11868295.
DOI: 10.1007/s00277-025-06201-8.
Carvalho L, Assis R, Montenegro C, da Rosa M, Pereira M, Pitta M
Int J Mol Sci. 2025; 25(24.
PMID: 39769262
PMC: 11676459.
DOI: 10.3390/ijms252413499.
Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery.
Cesar B, Braga W, Hamerschlak N, Durao Junior M
BMC Nephrol. 2024; 25(1):344.
PMID: 39390432
PMC: 11468068.
DOI: 10.1186/s12882-024-03717-5.
Current progress in CAR-based therapy for kidney disease.
Zhang D, Sun D
Front Immunol. 2024; 15:1408718.
PMID: 39234257
PMC: 11372788.
DOI: 10.3389/fimmu.2024.1408718.
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease.
Derudas D, Chiriu S
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204135
PMC: 11357053.
DOI: 10.3390/ph17081029.
Crystalline Light Chain Casts and Hypercalcemia Induced Acute Kidney Injury: A Rare Presentation of Multiple Myeloma.
Nishigaito T, Mitsumoto K, Katsunuma R, Hirai Y, Yamashita C, Mizumoto A
Intern Med. 2023; 63(12):1751-1755.
PMID: 37926541
PMC: 11239252.
DOI: 10.2169/internalmedicine.2603-23.
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
Jian Y, Chang L, Shi M, Sun Y, Chu X, Xue H
Blood Adv. 2023; 7(24):7581-7584.
PMID: 37922425
PMC: 10733092.
DOI: 10.1182/bloodadvances.2023011428.
Multiple Myeloma and the Role of Bisphosphonates in Its Management.
Tanveer N, Hussein S, Pingili S, Makkena V, Jaramillo A, Awosusi B
Cureus. 2023; 15(9):e45270.
PMID: 37846237
PMC: 10576843.
DOI: 10.7759/cureus.45270.
Analysis of complications and revisions after spine surgery in 270 multiple myeloma patients with spinal involvement.
Zijlstra H, Pierik R, Crawford A, Tobert D, Wolterbeek N, Oosterhoff J
Eur Spine J. 2023; 32(12):4335-4354.
PMID: 37707603
DOI: 10.1007/s00586-023-07903-1.
Validation of a Diagnostic Model to Differentiate Multiple Myeloma from Bone Metastasis.
Phinyo P, Jarupanich N, Lumkul L, Phanphaisarn A, Poosiripinyo T, Sukpanichyingyong S
Clin Epidemiol. 2023; 15:881-890.
PMID: 37522153
PMC: 10377591.
DOI: 10.2147/CLEP.S416028.
Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma.
Cerchione C, Grant S, Ailawadhi S
Am Soc Clin Oncol Educ Book. 2023; 43:e390202.
PMID: 37167570
PMC: 10798363.
DOI: 10.1200/EDBK_390202.
Acute kidney injury in autologous hematopoietic stem cell transplant for patients with lymphoma - KDIGO classification with creatinine and urinary output criteria: a cohort analysis.
Rodrigues N, Branco C, Costa C, Marques F, Neves M, Vasconcelos P
Ren Fail. 2023; 45(1):2183044.
PMID: 36856327
PMC: 9980396.
DOI: 10.1080/0886022X.2023.2183044.
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients-The DIADEM study from the chronic malignancies working party of the EBMT.
Waszczuk-Gajda A, Gras L, de Wreede L, Sirait T, Illes A, Ozkurt Z
Bone Marrow Transplant. 2023; 58(4):424-429.
PMID: 36681775
DOI: 10.1038/s41409-023-01915-7.
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
Ramasamy K, Iqbal G, Brouwer R, Stalker V, Akhtar S, Varghese S
Blood Cancer J. 2022; 12(11):162.
PMID: 36446771
PMC: 9708638.
DOI: 10.1038/s41408-022-00758-7.
[The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].
Zhonghua Xue Ye Xue Za Zhi. 2022; 43(4):265-271.
PMID: 35680623
PMC: 9189483.
DOI: 10.3760/cma.j.issn.0253-2727.2022.04.001.
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.
Dimopoulos M, Mikhael J, Terpos E, Leleu X, Moreau P, Blade J
Ther Adv Hematol. 2022; 13:20406207221088458.
PMID: 35392438
PMC: 8980434.
DOI: 10.1177/20406207221088458.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Capra M, Martin T, Moreau P, Baker R, Pour L, Min C
Haematologica. 2021; 107(6):1397-1409.
PMID: 34647444
PMC: 9152981.
DOI: 10.3324/haematol.2021.279229.